TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Australian Clinical Labs Ltd ( (AU:ACL) ) is now available.
Australian Clinical Labs Ltd announced the cessation of 550,000 fully paid ordinary securities as part of an on-market buy-back, effective November 19, 2025. This move is likely aimed at optimizing the company’s capital structure and could have implications for shareholder value and market perception.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, primarily providing pathology services and diagnostic testing. The company focuses on delivering high-quality laboratory services across Australia, catering to both individual patients and healthcare providers.
Average Trading Volume: 1,003,064
Technical Sentiment Signal: Sell
Current Market Cap: A$518.3M
For detailed information about ACL stock, go to TipRanks’ Stock Analysis page.